ArticleFrontiers in endocrinology2022
Characteristics of Gut Microbiome and Its Metabolites, Short-Chain Fatty Acids, in Children With Idiopathic Short Stature.
Article in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 23 citations in OpenAlex.
- Trial
- Gut microbiota profiles in Korean children with growth hormone deficiency: a case-control study.Clinical and experimental pediatrics · 2026Article
- Probiotic Bacteria in Stimulating Human Physiological Responses: Metabolic Function and Overall Health.Foods (Basel, Switzerland) · 2026Review
- Host genetic variation and gut microbiome in pediatric diseases.Chinese medical journal · 2026Review
- Children with idiopathic short stature and growth hormone deficiency exhibit similar changes in gut microbiota.Endocrine journal · 2025Article
- Dysbiosis of gut microbiota with enriched pro-inflammatory species in children with idiopathic short stature: a case-control study.Scientific reports · 2025Article
- Gut microbiota signatures in food allergy children without and with malnutrition: a cross-sectional study.BMC pediatrics · 2025Article
- Gut-brain-liver axis in growth hormone deficiency: role of microbiota-derived short-chain fatty acids in ethnic variability and therapeutic development.Frontiers in public health · 2025Review
- Gut microbiome and short-chain fatty acids associated with the efficacy of growth hormone treatment in children with short stature.Frontiers in pediatrics · 2025Article
- The critical role of diet, exercise, and sleep in shaping the gut microbiota of children with idiopathic short stature: a Retrospective study.Frontiers in immunology · 2025Article
- Gas Chromatography-Mass Spectrometry-Based Analyses of Fecal Short-Chain Fatty Acids (SCFAs): A Summary Review and Own Experience.Biomedicines · 2024Review
- Gut microbiota and metabolic changes in children with idiopathic short stature.BMC pediatrics · 2024Article
- Impact of different growth hormone levels on gut microbiota and metabolism in short stature.Pediatric research · 2024Article
- Children with idiopathic short stature have significantly different gut microbiota than their normal height siblings: a case-control study.Frontiers in endocrinology · 2024Article
- Toxicity evaluation of processing Evodiae fructus based on intestinal microbiota.Frontiers in microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The gut microbiome is important for host nutrition and metabolism. Whether the gut microbiome under normal diet regulate human height remains to be addressed. Our study explored the possible relationship between gut microbiota, its metabolic products and the pathogenesis of idiopathic short stature disease (ISS) by comparing the gut microbiota between children with ISS and of normal height, and also the short-chain fatty acids (SCFAs) produced by the gut microbiota. Methods: The subjects of this study were 32 prepubescent children aged 4-8 years. The fecal microbial structure of the subjects was analyzed by 16S rRNA high-throughput sequencing technology. The concentrations of SCFAs in feces were determined by gas chromatography-mass spectrometry. Results: The richness of gut microbiota in ISS group was decreased, and the composition of gut microbiota was significantly different between ISS group and control group. The relative abundance of nine species including family Ruminococcaceae and genera Conclusions: The composition of gut microbiota and the change in its metabolite levels may be related to ISS pathogenesis. Strains with increased or decreased specificity could be used as biomarkers to diagnose ISS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.